(Q37948079)

25 August 2017

title

The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications (English)

1 reference

25 August 2017

2

1 reference

25 August 2017

Józefa Wesierska-Gadek

series ordinal

1

object named as

Józefa Węsierska-Gądek

1 reference

25 August 2017

language of work or name

English

0 references

publication date

21 October 2011

1 reference

Expert Opinion on Investigational Drugs

25 August 2017

published in

1 reference

25 August 2017

volume

20

1 reference

25 August 2017

issue

12

1 reference

25 August 2017

page(s)

1611-1628

1 reference

New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Linking cyclins to transcriptional control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Lost in transcription: p21 repression, mechanisms, and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cell cycle proteins in epithelial cell differentiation: implications for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Retinoblastoma promotes definitive erythropoiesis by repressing Id2 in fetal liver macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Oestrogen receptors - an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Estrogen signaling: a subtle balance between ER alpha and ER beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin-dependent kinases: engines, clocks, and microprocessors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Animal cell cycles and their control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Translational control of cyclins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Secrets of a double agent: CDK7 in cell-cycle control and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Structural basis of cyclin-dependent kinase activation by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Gene expression changes in response to E2F1 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin a is required for the onset of DNA replication in mammalian fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Accumulation of cyclin E is not a prerequisite for passage through the restriction point

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin A promotes S-phase entry via interaction with the replication licensing factor Mcm7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Human cyclin A is required for mitosis until mid prophase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin D1 provides a link between development and oncogenesis in the retina and breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Molecular regulation of adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation, and adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Ki67 in breast cancer: prognostic and predictive potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclins and CDKS in development and cancer: lessons from genetically modified mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cell cycle control in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Defining a role for c-Myc in breast tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

MicroRNA gene expression deregulation in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin D1 and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin D1 in breast cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin E and survival in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin E as a prognostic and predictive marker in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Deregulation of cyclin E in human cells interferes with prereplication complex assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Deregulated cyclin E induces chromosome instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Redundant cyclin overexpression and gene amplification in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

A novel interaction between HER2/neu and cyclin E in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The nuclear receptor superfamily: the second decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Estrogen receptor variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Adenosine 3',5'-monophosphate in rat uterus: acute elevation by estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The expanding cosmos of nuclear receptor coactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Molecular basis of agonism and antagonism in the oestrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Proximal events in signaling by plasma membrane estrogen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Uterine estrogen receptor in vivo: phosphorylation of nuclear specific forms on serine residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Estrogen receptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The steroid and thyroid hormone receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

DNA regulatory elements for steroid hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Regulation of gene expression by nuclear hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Hes-6, an inhibitor of Hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

A quantitative protein interaction network for the ErbB receptors using protein microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Role of HER2/neu in tumor progression and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

New targeted therapies in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cell cycle kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin-dependent kinase inhibitors: a survey of recent patent literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

CDK inhibitors: from the bench to clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Novel potent pharmacological cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Inhibition of cyclin-dependent kinases by purine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Mechanism of H-8 inhibition of cyclin-dependent kinase 9: study using inhibitor-immobilized matrices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Flavopiridol, an inhibitor of transcription: implications, problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

A novel liposomal formulation of flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Activation of p53 by roscovitine-mediated suppression of MDM2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Controlling the elongation phase of transcription with P-TEFb

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Meta-analysis of soy intake and breast cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Demographics and perceptions of barriers toward breast cancer screening among Asian-American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Adolescent and adult soy intake and risk of breast cancer in Asian-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

The role of early life genistein exposures in modifying breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Genistin (an Isoflavone Glucoside) and its Aglucone, Genistein, from Soybeans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Strain-dependent epithelial defects in mice lacking the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Cyclin D1 protein expression and function in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.628985

10.1517/13543784.2011.628985

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference